• Interview with Victor Bulto, President, US, Novartis

  • 2024/03/28
  • 再生時間: 44 分
  • ポッドキャスト

Interview with Victor Bulto, President, US, Novartis

  • サマリー

  • In this important podcast episode, we interview Victor Bulto, President, US for Novartis, to discuss the company's efforts to develop groundbreaking treatments while ensuring accessibility and affordability for patients. We delve into how the pharmaceutical industry navigates numerous post-FDA approval barriers to launch new drugs and the importance of market access, patient support services, and a commitment by manufacturers to provide patient assistance and other support for patients.

    Victor Bulto, President, Novartis

    Novartis

    FDA

    Institute for Clinical and Economic Review (ICER)

    American Heart Association (AHA)

    Inflation Reduction Act (IRA)

    Pharmacy Benefit Manager (PBM)

    Medicare

    Medical terminology referenced in this episode:

    Cell therapy: CART-T

    Radioligand therapy

    RNA

    Entresto

    Molecular glues

    Targeted protein degradation

    Antisense oligonucleotides

    Small interfering RNAs: siRNAs

    LDL cholesterol

    COVID

    Hematological malignancies

    Refractory autoimmune diseases

    Questions or comments?
    Email us at comments@prescriptionforbetteraccess.com.
    Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

    続きを読む 一部表示

あらすじ・解説

In this important podcast episode, we interview Victor Bulto, President, US for Novartis, to discuss the company's efforts to develop groundbreaking treatments while ensuring accessibility and affordability for patients. We delve into how the pharmaceutical industry navigates numerous post-FDA approval barriers to launch new drugs and the importance of market access, patient support services, and a commitment by manufacturers to provide patient assistance and other support for patients.

Victor Bulto, President, Novartis

Novartis

FDA

Institute for Clinical and Economic Review (ICER)

American Heart Association (AHA)

Inflation Reduction Act (IRA)

Pharmacy Benefit Manager (PBM)

Medicare

Medical terminology referenced in this episode:

Cell therapy: CART-T

Radioligand therapy

RNA

Entresto

Molecular glues

Targeted protein degradation

Antisense oligonucleotides

Small interfering RNAs: siRNAs

LDL cholesterol

COVID

Hematological malignancies

Refractory autoimmune diseases

Questions or comments?
Email us at comments@prescriptionforbetteraccess.com.
Find us on social media! Follow us on X, LinkedIn, YouTube and Threads.

Interview with Victor Bulto, President, US, Novartisに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。